TET2 Loss Dysregulates the Behavior of Bone Marrow Mesenchymal Stromal Cells and Accelerates Tet2^-/--Driven Myeloid...

Area of Science:

• Epigenetics
• Hematology
• Stem Cell Biology

Background:

• TET2 (Ten-Eleven Translocation 2) is a methylcytosine dioxygenase crucial for regulating DNA methylation patterns.
• While TET2's role in hematopoietic stem/progenitor cells (HSPCs) is well-established, its function in bone marrow mesenchymal stromal cells (BMSCs) is largely unexplored.

Purpose of the Study:

• To investigate the role of TET2 in BMSC function, osteoblast differentiation, and its impact on myeloid malignancy progression.
• To elucidate the epigenetic mechanisms by which TET2 loss affects BMSC behavior and supports cancer development.

Main Methods:

• Utilized genetic manipulation to induce Tet2 loss in BMSCs.
• Assessed BMSC proliferation, self-renewal, and osteogenic differentiation capacity in vitro.
• Evaluated the impact of Tet2-deficient BMSCs on HSPC support and myeloid malignancy progression in vivo.
• Analyzed changes in 5-methylcytosine hydroxylation and gene expression profiles in BMSCs.

Main Results:

• Tet2 loss in BMSCs significantly increased cell proliferation and self-renewal capabilities.
• BMSCs lacking TET2 exhibited enhanced osteoblast differentiation potential.
• Tet2-deficient BMSCs promoted the progression of Tet2-deficiency-mediated myeloid malignancies.
• Loss of TET2 dysregulated 5-methylcytosine hydroxylation and altered the expression of key genes involved in BMSC functions.

Conclusions:

• TET2 plays a critical role in maintaining BMSC homeostasis, osteoblast differentiation, and supporting hematopoiesis.
• Dysregulation of TET2 in BMSCs contributes to myeloid malignancy progression through epigenetic alterations.
• These findings highlight BMSCs as key players in the context of epigenetic dysregulation and cancer development.